张承宁, 段俗言, 袁杨刚, 朱敬凤, 黄智敏, 孙彬, 张波, 毛慧娟, 邢昌赢. 影响他克莫司治疗特发性膜性肾病疗效的相关因素及其预测价值分析[J]. 临床肾脏病杂志, 2022, 22(10): 807-813. DOI: 10.3969/j.issn.1671-2390.2022.10.003
    引用本文: 张承宁, 段俗言, 袁杨刚, 朱敬凤, 黄智敏, 孙彬, 张波, 毛慧娟, 邢昌赢. 影响他克莫司治疗特发性膜性肾病疗效的相关因素及其预测价值分析[J]. 临床肾脏病杂志, 2022, 22(10): 807-813. DOI: 10.3969/j.issn.1671-2390.2022.10.003
    Zhang Cheng-ning, Duan Su-yan, Yuan Yang-gang, Zhu Jing-feng, Huang Zhi-min, Sun Bin, Zhang Bo, Mao Hui-juan, Xing Chang-ying. Analyses of factors affecting and predicting the efficacy of tacrolimus in patients with idiopathic membranous nephropathy[J]. Journal of Clinical Nephrology, 2022, 22(10): 807-813. DOI: 10.3969/j.issn.1671-2390.2022.10.003
    Citation: Zhang Cheng-ning, Duan Su-yan, Yuan Yang-gang, Zhu Jing-feng, Huang Zhi-min, Sun Bin, Zhang Bo, Mao Hui-juan, Xing Chang-ying. Analyses of factors affecting and predicting the efficacy of tacrolimus in patients with idiopathic membranous nephropathy[J]. Journal of Clinical Nephrology, 2022, 22(10): 807-813. DOI: 10.3969/j.issn.1671-2390.2022.10.003

    影响他克莫司治疗特发性膜性肾病疗效的相关因素及其预测价值分析

    Analyses of factors affecting and predicting the efficacy of tacrolimus in patients with idiopathic membranous nephropathy

    • 摘要: 目的 该研究旨在分析临床指标对他克莫司(tacrolimus,FK506)治疗特发性膜性肾病(idiopathic membranous nephropathy,IMN)的影响及预测价值。方法 采用回顾性的研究方法纳入76例确诊IMN的患者,口服FK506(0.05~0.075 mg·kg-1·d-1)和中等剂量泼尼松(0.5 mg·kg-1·d-1),随访周期24周。收集患者临床病理指标、治疗效果和不良反应的数据。根据疗效分为三组:完全缓解组(complete remission,CR)、部分缓解组(partial remission,PR)、无效组(no remission,NR)。分析临床指标对疗效的影响以及预测价值。结果 三组FK506的谷浓度无差异,谷浓度与缓解率之间无线性相关,4~6 μg/L的血药浓度区间缓解率高于其他浓度区间(P<0.05)。男性缓解率低于女性。基线血肌酐值CR组、PR组显著低于NR组[(69.18±13.61)μmol/L、(80.20±16.44)μmol/L比(92.53±22.60)μmol/L,P<0.05];估算肾小球滤过率(estimated glomerular filtration rate,eGFR)CR组、PR组显著高于NR组[(95.89±16.46) mL·min-1·1.73 m-2、(96.96±17.01) mL·min-1·(1.73 m2-1比(78.70±20.01) mL·min-1·(1.73 m2-1P<0.05];血尿酸CR组显著低于PR组、NR组[(344.79±81.85)μmol/L比(405.72±89.77)μmol/L、(382.48±96.32)μmol/L];肾小管萎缩CR组显著低于PR、NR组(1例比18例、10例,P<0.01)。多因素COX回归分析显示eGFR、血清白蛋白可以作为独立因素预测患者的疗效。结论 男性、基线血肌酐、eGFR及肾小管萎缩是影响疗效的关键因素。eGFR、血清白蛋白可以作为独立因素预测患者的疗效。

       

      Abstract: Objective To explore the factors of affecting and predicting the therapeutic efficacy of tacrolimus(FK506)in patients with idiopathic membranous nephropathy(IMN). Methods A total of 76 IMN patients receiving oral FK506(0.05-0.075 mg·kg-1·d-1)plus prednisone(0.5 mg·kg-1·d-1) were recruited. Clinical characteristics,pathological indicators,therapeutic effect and adverse reactions were recorded at baseline and during 24-week treatment. According to curative effect,they were divided into three groups of complete remission(CR),partial remission(PR)and no remission(NR). The impact of clinical characteristics on efficacy and outcome was examined. Results No difference existed in average blood trough concentration of tacrolimus among three groups. There was no correlation between blood trough concentration and remission rate. The remission rate in trough concentration range of 4-6 μg/L was higher than other concentration ranges. The remission rate was lower in males than that in females. Baseline serum creatinine was significantly lower in CR/PR group than that in NR group [(69.18±13.61)μmol/L、(80.20±16.44)μmol/L vs(92.53±22.60)μmol/L, P<0.05];eGFR was significantly higher in CR/PR group than that in NR group[(95.89±16.46)mL·min-1· (1.73 m-2)、 (96.96±17.01)mL·min-1· (1.73 m2-1 vs(78.70±20.01)mL·min-1· (1.73 m2-1P<0.05];serum uric acid was significantly lower in CR group than that in PR/NR group[(344.79±81.85)μmol/L vs (405.72±89.77)μmol/L、(382.48±96.32)μmol/L];tubular atrophy(TA)was significantly lower in CR group than that in PR/NR group(1 vs 18、 10, P<0.01). Multivariate COX regression analysis indicated that eGFR and serum albumin were independent factors for predicting the efficacy of tacrolimus in IMN patients. Conclusion Male,baseline creatinine,eGFR and TA are four key influencing factors of efficacy. And eGFR and serum albumin are independent predictive factors of outcomes.

       

    /

    返回文章
    返回